C4 (CCCC) Rises in Active Trading for June 23

Equities Staff  |

C4 Therapeutics Inc (NASDAQ:CCCC) stock was among today's market movers, finishing trading higher 6.93% to $6.48 on June 23.

940,383 shares traded today in comparison to the 30-day daily average of 852,793 shares.

The company's stock has moved 81.18% so far in 2022.

C4 shares have traded in a range between $4.84 and $51.21 over the past twelve months.

The company anticipates its next earnings on 2022-08-10.

For technical charts, analysis, and more on C4 visit the company profile.

About C4 Therapeutics Inc

C4 Therapeutics is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity.

To get more information on C4 Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: C4 Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade

Market Movers

Sponsored Financial Content